Marstacimab

Marstacimab
Clinical data
Other namesPF-06741086
ATC code
  • None
Identifiers
CAS Number
DrugBank
UNII
KEGG

Marstacimab is an experimental monoclonal antibody intended for the treatment of hemophilia A and B.[1] It is being developed by Pfizer.[2]

  1. ^ Cite error: The named reference Hympavzi EPAR was invoked but never defined (see the help page).
  2. ^ "FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B". Pfizer (Press release). 9 December 2023. Retrieved 21 September 2024.